% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • justarook04 justarook04 Apr 8, 2014 2:38 PM Flag

    The AstraZeneca rumor was for $1B in September

    We ALL think that will never happen but the way the PPS is wandering downwards, $1B might be possible (as an offer). I firmly disagree if that were to ever materialize but, $2B would be more likely. Tomorrow should tell us something and I think JAD might have something with additional coverage possible after the presentation.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It does my brain in that there are so many people here who wouldn't DREAM of selling a house or a car without making absolutely sure that the price they are offered is reasonable compared with the going price of a house or car in a similar condition/location - yet seem to be under the impression that other investors would be willing to sell a multi-BILLION dollar asset just because the offer is a lot of money :-)

      • 1 Reply to fud.fighter2
      • FUD, I didn't post this because this is what I would prefer. It is just a "pie in the sky" element that someone posted on the Internet last week. With this downtrend, ANY, positive news or possibilities are better than thinking the worse. My minimum (sorry) has always been $2B which equates to $50/shr (with 40M shares). That exceeds Schimmer's PT even though the facts will blow these numbers out of the water. Tomorrow should help.

        Sentiment: Buy

    • An offer is just that, an offer. But it is premature unless there is an "earn out" clause that allows shareholders to maximize valuation. We now can say with certainty we have the only product available that treats NTM effectively, will be a valuable adjunct to existing products for CF, will be the only product in-market for short stature in a few years and may well be valuable for any number of other applications that have been listed here and are found on various presentations the company has made. The sooner they file with the FDA and the EMEA the better. In the meantime, they also need to announce who they will partner with in markets they don't want to service directly.

      Sentiment: Strong Buy

14.66-0.37(-2.46%)Sep 28 4:00 PMEDT